GB2494741B - A method for diagnosing or determining the prognosis of colorectal cancer (crc) using novel autoantigens: gene expression guided autoantigen discovery - Google Patents

A method for diagnosing or determining the prognosis of colorectal cancer (crc) using novel autoantigens: gene expression guided autoantigen discovery

Info

Publication number
GB2494741B
GB2494741B GB201211395A GB201211395A GB2494741B GB 2494741 B GB2494741 B GB 2494741B GB 201211395 A GB201211395 A GB 201211395A GB 201211395 A GB201211395 A GB 201211395A GB 2494741 B GB2494741 B GB 2494741B
Authority
GB
United Kingdom
Prior art keywords
gene expression
colorectal cancer
prognosis
crc
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB201211395A
Other versions
GB2494741A (en
GB201211395D0 (en
Inventor
Mark Jq Lim
Christopher Sears
Kenneth J Rothschild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambergen Inc
Original Assignee
Ambergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/533,036 external-priority patent/US20130022987A1/en
Application filed by Ambergen Inc filed Critical Ambergen Inc
Publication of GB201211395D0 publication Critical patent/GB201211395D0/en
Publication of GB2494741A publication Critical patent/GB2494741A/en
Application granted granted Critical
Publication of GB2494741B publication Critical patent/GB2494741B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The invention relates to a method of detecting autoantibodies related to colorectal cancer in an individual comprising contacting a test sample from an individual with one or more target antigens selected from MAP4K4 and IGFBP3 and detecting any antibodies that bind to said antigens. The sample may also be contacted with target antigens selected from p53 or IGF2BP2 to detect autoantibodies to said antigens. Also provided in a further embodiment is a method for identifying antibodies related to cancer by comparing gene expression levels of cancer cells compared to normal cells, assaying body fluid from an individual with cancer for antibodies to the genes only activated in the cancer cells and identifying an antibody.
GB201211395A 2011-06-27 2012-06-27 A method for diagnosing or determining the prognosis of colorectal cancer (crc) using novel autoantigens: gene expression guided autoantigen discovery Expired - Fee Related GB2494741B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501466P 2011-06-27 2011-06-27
US13/533,036 US20130022987A1 (en) 2011-06-27 2012-06-26 Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery

Publications (3)

Publication Number Publication Date
GB201211395D0 GB201211395D0 (en) 2012-08-08
GB2494741A GB2494741A (en) 2013-03-20
GB2494741B true GB2494741B (en) 2013-11-06

Family

ID=46704290

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201211395A Expired - Fee Related GB2494741B (en) 2011-06-27 2012-06-27 A method for diagnosing or determining the prognosis of colorectal cancer (crc) using novel autoantigens: gene expression guided autoantigen discovery

Country Status (1)

Country Link
GB (1) GB2494741B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114836A1 (en) * 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
US20100297014A1 (en) * 2007-10-10 2010-11-25 Paul Jenkins Method of detecting the risk of cancer using genetic markers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297014A1 (en) * 2007-10-10 2010-11-25 Paul Jenkins Method of detecting the risk of cancer using genetic markers
WO2009114836A1 (en) * 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cancer Epidemiol; Vol 12, pp 136-143 (2003). Zhang et al. "Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens" *
Clin Cancer Res; Vol 9, pp 5120-5126 (2003). Koziol et al. "Recursive partitioning as an approach to selection of immune markers for tumour diagnosis" *
Hepato-Gastroenterology; Vol 54, pp 1422-1425 (2007). Nozoe et al. "Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal cancer" *
Int J Oncology; Vol 26, pp 311-317. Himoto et al "Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma" *
J Pathol; Vol 220, pp 475-489 (2009). Hao et al. "A five gene signature as a potential predictor of metastasis and survival in colorectal cancer" *
Scandinavian J Immunol; Vol 69, pp 57-63 (2008). Liu et al. "Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer" *

Also Published As

Publication number Publication date
GB2494741A (en) 2013-03-20
GB201211395D0 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
US20230393150A1 (en) Methods and algorithms for aiding in the detection of cancer
Norman et al. Anti‐kelch‐like 12 and anti‐hexokinase 1: novel autoantibodies in primary biliary cirrhosis
Zhou et al. Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery
WO2012061759A3 (en) Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
Chang et al. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection
NZ706187A (en) Assays for the detection of anti-tnf drugs and autoantibodies
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
WO2014144129A3 (en) Biomarkers and methods for predicting preterm birth
IN2015DN01855A (en)
EA201370063A1 (en) PHOSPHOLYPIDE CANCER
MX2014001377A (en) Method for detecting pancreatic cancer.
MX2009008307A (en) Methods and materials for identifying the origin of a carcinoma of unknown primary origin.
MX2019006098A (en) Antibody assay.
Ding et al. Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma
RU2012148711A (en) METHOD AND KIT FOR DIAGNOSIS OF A MALIGNANT TUMOR
WO2009121024A3 (en) Methods for detecting antibodies
Rosser et al. Urinary biomarkers of bladder cancer: an update and future perspectives
JP2017509351A5 (en)
Wang et al. Overexpression of nuclear β-catenin in rectal adenocarcinoma is associated with radioresistance
RU2019104870A (en) COMBINED TEST FOR THE PRESENCE OF COLORECTAL CANCER
Chiam et al. Identification of microRNA biomarkers of response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing
Roney et al. IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread
EP2415877A3 (en) Means and methods for diagnosing pancreatic cancer
WO2019089858A3 (en) Methods of assessing or monitoring a response to a cell therapy
GB2494741B (en) A method for diagnosing or determining the prognosis of colorectal cancer (crc) using novel autoantigens: gene expression guided autoantigen discovery

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20160627